Arizona Tribune - Hemogenyx raises £570,000 and Director's Dealing

LONDON, UK / ACCESS Newswire / August 26, 2025 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Hemogenyx Secures £570,000 to continue its Phase 1 Clinical Trials And Director's Dealing

Introduction

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised gross proceeds of £ 570,000 via an allotment to Vladislav Sandler of 316,667 new ordinary shares of £0.01 each ("New Ordinary Shares") at an issue price of 180p, representing a premium to the market price (the "Issue Price").

The net proceeds of this fundraise will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ("HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ("R/R AML"). As shareholders will be aware, the Company has made significant strides in its Phase 1 clinical trial of HG-CT-1, with early trials supporting growing confidence in both safety and potential efficacy.

Issuance of the New Ordinary Shares

The Company is currently unable to issue and admit New Ordinary Shares without either the publication of an FCA approved prospectus or relying upon an exemption to the requirement to issue a prospectus.

Consequently, this fundraise involves the agreement by Vladislav Sandler, CEO and director of the Company, to subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.

Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed to direct their issue to a small group of individual investors who made an approach wishing to make a new investment in the Company.

Warrants

Concurrent with the purchase of the New Ordinary Shares, the new investor group will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 180p ("Exercise Price"), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price.

Total Voting Rights

Application will be made for the 316,667 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 4 September 2025 ("Admission").

Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 5,043,896.

The above figure of 5,043,896 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company will keep the market informed of future developments as trials proceed.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are pleased to have attracted funding from a small group of dedicated investors at a premium to the market price. This reflects investors' confidence in the progress made by the Company to date and in its long-term prospects. The fact that the raise was completed at a premium to the market price demonstrates this confidence and shows that the investors see considerable upside potential in our share price as we advance HG-CT-1 through clinical development"

UK Market Abuse Regulation (UK MAR) Disclosure

Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.

Director's Dealing Notification

Enquiries:

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

R.Lee--AT